Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials

Fig. 3

Subgroup analysis for additional Capecitabine use in early-staged TNBC. A summarized HR for DFS in unselected TNBC patients receiving A&T based regimens; (B) summarized HR for DFS in unselected TNBC patients with LN negative; (C) summarized HR for DFS in unselected TNBC patients with LN positive; (D) summarized HR for DFS in unselected TNBC patients with LN positive, capecitabine ≥6 cycles or 18 weeks; (E) summarized HR for DFS in unselected premenopausal TNBC patients; (F) summarized HR for DFS in unselected postmenopausal TNBC patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us